Pharmaceuticals - Community Register


Community list of not active orphan medicinal products


Product information


EU orphan designation number: EU/3/12/1071
Active ingredient: Canakinumab
Indication: Treatment of tumour necrosis factor receptor-associated periodic syndrome
Sponsor: Novartis Europharm Limited
Frimley Business Park, Camberley GU16 7SR, United Kingdom

   Public summary of scientific opinion    

European Commission proceduresGoto top of the page

Close date procedure Procedure type EMEA number Decision summary publ decision docs annex
12/11/2012 Orphan designation EMA/OD/060/12 (2012)8204 of 08/11/2012
29/08/2014 Change of name and/or address of sponsor
02/06/2015 Removal of orphan designation from Community Register